New protein injection shows promise in early Alzheimer's trial
Disease control
Completed
This early-phase study tests a lab-made protein (recombinant human serum albumin) in 30 people with mild to moderate Alzheimer's. Participants receive one of three doses to check safety and any effect on thinking skills. The goal is to see if this treatment can help control the d…
Early phase 1 • Sponsor: Shenzhen Protgen Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC